No compulsion of saying Om during Yoga Day: Ayush Minister

New Delhi, Jun 18: Sonia Gandhi on Wednesday removed Sanjay Jha as a party spokesperson, days after he wrote a newspaper article criticising the party. She also approved the appointment of Abhishek Dutt and Sadhna Bharti as national media panelists for the Congress.

"Congress president has also approved that Sanjay Jha be dropped as AICC spokesperson with immediate effect," the party said in an official statement.

In the article published a few days ago, Mr Jha had said, "The Congress has demonstrated extraordinary lassitude, and its lackadaisical attitude towards its own political obsolescence is baffling..."

"I would like to call a spade a spade here and a shovel: there has been no serious effort to get the party up and running with any sense of urgency," he had said in the article in a national newspaper.

"There are many in the party who cannot comprehend this perceptible listlessness. For someone like me, for instance, permanently wedded to Gandhian philosophy and Nehruvian outlook that defines the Congress, it is dismaying to see its painful disintegration," he had said.

New Delhi, Mar 19: Former Chief Justice of India Ranjan Gogoi took oath as Rajya Sabha MP on Thursday.

Gogoi's wife Rupanjali Gogoi, daughter, and son in law were also present in Parliament.

Congress staged a walkout from the Rajya Sabha over Gogoi's membership to the House.

Meanwhile, Union Minister Ravishankar Prasad welcomed Gogoi in the Rajya Sabha.

President Ram Nath Kovind had nominated the former CJI to the Rajya Sabha on March 16.

Gogoi served as the 46th Chief Justice of India from October 3, 2018, to November 17, 2019.

On November 9, 2019, a five-judge Bench headed by him had delivered the verdict in the long-pending Ramjanmabhoomi case.

Bengaluru, Apr 30: Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.

Favipiravir, manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.

"After having successfully developed the API and the formulations ... Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India," Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement. 

The Drug Controller General of India, the country's drug regulator, did not immediately respond to Reuters request for comment.

On Wednesday, another Indian pharmaceutical company, Strides Pharma Science Ltd, said it had developed and commercialized favipiravir antiviral tablets, and had applied to Indian drug authorities to start trials.

Shares of Mumbai-based Glenmark Pharmaceuticals, which rose as much as 8.9% to 359 rupees ($4.78), was trading up 5.9%, as of 0407 GMT.